Incyte (INCY) and CMS agree Medicaid pricing terms for Jakafi; potential implications for Medicaid rebates, JAKAFI revenue concentration and financial estimates.
Incyte (INCY) closes acquisition of Vega Therapeutics subsidiary on Jul 6, 2026. Deal aligns with pipeline strategy; cash+marketables $3.6B (12/31/2025).